NAT2

Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®

Retrieved on: 
Thursday, November 2, 2023
CORAL, Fasting, Patent, Rare, United States Patent and Trademark Office, Orange Book, Catalyst Pharmaceuticals, Amifampridine, Approved Drug Products with Therapeutic Equivalence Evaluations, Lambert–Eaton myasthenic syndrome, Tablet, Patient, NAT2, Pharmaceutical industry, Catalysis

FIRDAPSE is the only approved treatment available in the U.S. for Lambert-Eaton myasthenic syndrome.

Key Points: 
  • FIRDAPSE is the only approved treatment available in the U.S. for Lambert-Eaton myasthenic syndrome.
  • "We are very pleased to receive these patent notifications from the USPTO.
  • "These patent allowances strengthen our cumulative understanding of the uniqueness of FIRDAPSE and bolster its strong intellectual property estate offering enhanced patent protection," stated Dr. Steven Miller, Chief Operating Officer and Chief Scientific Officer of Catalyst.
  • Preparations are already in motion to include these additional FIRDAPSE patents in the FDA Orange Book post-grant, bringing the total listed patent count to eight."

Catalyst Pharmaceuticals Further Strengthens FIRDAPSE® U.S. Patent Portfolio

Retrieved on: 
Wednesday, March 2, 2022
Amifampridine, Patient, LEMS, Adult, Patent, Population, Forward-looking statement, Seminal vesicles, K, Annual report, Tablet, United, FDA, New Drug Application, Exocytosis, NAT2, SEC, Company, Lambert–Eaton myasthenic syndrome, CORAL, Catalyst Pharmaceuticals, Potassium, Approved Drug Products with Therapeutic Equivalence Evaluations, USPTO, GLOBE, Degenerative disease, Pharmaceutical industry, Catalysis, Acetylcholine

CORAL GABLES, Fla., March 02, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that the United States Patent and Trademark Office ("USPTO") has notified Catalyst that an additional patent covering FIRDAPSE® (amifampridine) Tablets 10 mg, the Company's proprietary formulation of amifampridine, will issue on March 8, 2022, and that two additional patents will issue on March 15, 2022. FIRDAPSE is currently the only approved treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") in the U.S.

Key Points: 
  • FIRDAPSE is currently the only approved treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") in the U.S.
  • "As part of our portfolio strategy, we will continue to execute on our key initiatives to strengthen and protect the long-term commercial potential of FIRDAPSE, which currently has patent exclusivity protection in the U.S. until 2034."
  • Copies of Catalyst's filings with theSECare available from theSEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst.
  • Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.